Novo Nordisk Launches Higher Dose Wegovy in US With Pricing Below Eli Lilly's Zepbound

MT Newswires Live04-07 21:13

Novo Nordisk (NVO) said Tuesday it launched Wegovy HD, an injectable 7.2 milligram version of its popular weight-loss drug, in the US.

The company said the drug is priced at $399 per month for self-paying customers, a price that undercuts the cash prices for the higher doses of rival Eli Lilly's (LLY) Zepbound. Self-pay prices for the higher doses of Zepbound range from $499 to $699, according to Lilly's website.

Wegovy HD, with a dosage higher than the previously approved maximum of 2.4 mg, showed an average weight loss of about 21% at 72 weeks in a clinical trial, Novo Nordisk said.

The drug will be available nationwide through pharmacies and telehealth providers, the company said.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment